NASDAQ:TOCATocagen Stock Price, Forecast & News

$1.22

+0.01 (+0.83 %)

(As of 06/2/2020 09:48 AM ET)

Add

Compare

Today's Range

$1.19

Now: $1.22▼

$1.25

50-Day Range

$1.07

MA: $1.25▼

$1.57

52-Week Range

$0.42

Now: $1.22▼

$6.77

Volume268,449 shs

Average Volume442,976 shs

Market Capitalization$29.18 million

P/E RatioN/A

Dividend YieldN/A

Beta0.01

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
Tocagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.77, Tocagen has a potential upside of 45.4% from its current price of $1.22.
Amount of Analyst Coverage
Tocagen has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Tocagen has received 241 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tocagen has received 249 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tocagen has received 50.82% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote “Outperform” if you believe TOCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tocagen does not currently pay a dividend.
Dividend Growth
Tocagen does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tocagen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $196,566.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.90% of the stock of Tocagen is held by insiders.
Percentage Held by Institutions
Only 21.42% of the stock of Tocagen is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Tocagen are expected to grow in the coming year, from ($2.39) to $0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tocagen is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tocagen is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tocagen has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TOCA

Previous Symbol

CUSIPN/A

CIK1419041

Webwww.tocagen.com

Phone858-412-8400

Debt

Debt-to-Equity Ratio1.88

Current Ratio1.15

Quick Ratio1.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00

Price / Sales729.56

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.45 per share

Price / Book2.71

Profitability

EPS (Most Recent Fiscal Year)($2.69)

Net Income$-63,520,000.00

Net Margins-176,433.34%

Return on Equity-327.74%

Return on Assets-111.87%

Miscellaneous

Employees77

Outstanding Shares23,920,000

Market Cap$29.18 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive TOCA News and Ratings via Email

Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

Tocagen (NASDAQ:TOCA) Frequently Asked Questions

How has Tocagen's stock been impacted by COVID-19 (Coronavirus)?

Tocagen's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TOCA stock has decreased by 21.3% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tocagen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen.

When is Tocagen's next earnings date?

Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen.

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) announced its earnings results on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history.

What price target have analysts set for TOCA?

7 brokers have issued twelve-month target prices for Tocagen's shares. Their forecasts range from $1.00 to $3.32. On average, they expect Tocagen's share price to reach $1.77 in the next year. This suggests a possible upside of 45.4% from the stock's current price. View analysts' price targets for Tocagen.

Has Tocagen been receiving favorable news coverage?

News coverage about TOCA stock has been trending very positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tocagen earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutTocagen.

Are investors shorting Tocagen?

Tocagen saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,490,000 shares, an increase of 17.3% from the April 30th total of 1,270,000 shares. Based on an average trading volume of 2,200,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 8.3% of the company's shares are short sold. View Tocagen's Current Options Chain.

Who are some of Tocagen's key competitors?

Some companies that are related to Tocagen include Checkpoint Therapeutics (CKPT), InflaRx (LUMO), AcelRx Pharmaceuticals (ACRX), Catabasis Pharmaceuticals (CATB), Cyclerion Therapeutics (CYCN), ESSA Pharma (EPIX), Galmed Pharmaceuticals (GLMD), Recro Pharma (REPH), TapImmune (MRKR), TFF Pharmaceuticals (TFFP), Corvus Pharmaceuticals (CRVS), Eton Pharmaceuticals (ETON), Leap Therapeutics (LPTX), Genprex (GNPX) and Oncolytics Biotech (ONCY). View all competitors.

What other stocks do shareholders of Tocagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Amarin (AMRN), VBI Vaccines (VBIV), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX).

Who are Tocagen's key executives?

Tocagen's management team includes the following people:

Mr. Martin J. Duvall, CEO & Director (Age 57)
Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)

When did Tocagen IPO?

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Who are Tocagen's major shareholders?

Tocagen's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.98%), Geode Capital Management LLC (1.63%), State Street Corp (1.47%), Morgan Stanley (1.32%), MYDA Advisors LLC (0.70%) and Deutsche Bank AG (0.23%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber, Martin J Duvall and Steven Michael Oliveira. View institutional ownership trends for Tocagen.

Which institutional investors are selling Tocagen stock?

TOCA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, State Street Corp, Parametric Portfolio Associates LLC, Deutsche Bank AG, BlackRock Inc., and UBS Group AG. View insider buying and selling activity for Tocagen.

Which institutional investors are buying Tocagen stock?

TOCA stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, MYDA Advisors LLC, Geode Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber, Martin J Duvall, and Steven Michael Oliveira. View insider buying and selling activity for Tocagen.

How do I buy shares of Tocagen?

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tocagen's stock price today?

One share of TOCA stock can currently be purchased for approximately $1.22.

How big of a company is Tocagen?

Tocagen has a market capitalization of $29.18 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe.

What is Tocagen's official website?

The official website for Tocagen is www.tocagen.com.

How can I contact Tocagen?

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff